BR9908338A - Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes - Google Patents

Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes

Info

Publication number
BR9908338A
BR9908338A BR9908338-8A BR9908338A BR9908338A BR 9908338 A BR9908338 A BR 9908338A BR 9908338 A BR9908338 A BR 9908338A BR 9908338 A BR9908338 A BR 9908338A
Authority
BR
Brazil
Prior art keywords
sows
estrus
pseudopregnancy
ovulation
regulation
Prior art date
Application number
BR9908338-8A
Other languages
English (en)
Inventor
Patrick J Burns
Original Assignee
Thorn Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thorn Bioscience Llc filed Critical Thorn Bioscience Llc
Publication of BR9908338A publication Critical patent/BR9908338A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

<B>"MéTODO, COMPOSIçãO E DISPOSITIVO PARA A REGULAçãO DO CIO E DA OVULAçãO EM MATRIZES"<D>. São reveladas composições de liberação controlada e métodos para induzir a pseudogravidez em matrizes e porcas. Na incorporação preferencial, a presente invenção inclui microesferas de polilactídeo liberando estradiol 17ß em níveis fisiologicamente utilizáveis ao longo de um período de tempo entre cinco e trinta dias. Após a indução da pseudogravidez, a pseudogravidez pode ser encerrada e o cio pode ser induzido por meio de compostos tais como O PGF2<244>. As vantagens da indução da pseudogravidez seguida da indução do cio são que os padrões de procriação de um grande número de matrizes e porcas podem ser controlados.
BR9908338-8A 1998-02-19 1999-02-18 Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes BR9908338A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/026,463 US6028057A (en) 1998-02-19 1998-02-19 Regulation of estrus and ovulation in gilts
PCT/US1999/003441 WO1999042110A1 (en) 1998-02-19 1999-02-18 Regulation of estrus and ovulation in gilts

Publications (1)

Publication Number Publication Date
BR9908338A true BR9908338A (pt) 2000-10-10

Family

ID=21831965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908338-8A BR9908338A (pt) 1998-02-19 1999-02-18 Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes

Country Status (10)

Country Link
US (1) US6028057A (pt)
EP (1) EP1054675A1 (pt)
JP (1) JP2002503696A (pt)
KR (1) KR20010034494A (pt)
CN (1) CN1291101A (pt)
AU (1) AU2685099A (pt)
BR (1) BR9908338A (pt)
CA (1) CA2321102A1 (pt)
PL (1) PL342402A1 (pt)
WO (1) WO1999042110A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
AU2003201410B2 (en) * 2002-01-24 2008-07-03 Virbac Corporation Sustained release pharmaceutical composition
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
JP4721752B2 (ja) * 2005-04-06 2011-07-13 独立行政法人科学技術振興機構 妊娠状態における薬物代謝予測法
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
GB0613333D0 (en) * 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20080160065A1 (en) * 2006-07-12 2008-07-03 Janet Anne Halliday Drug delivery polymer with hydrochloride salt of clindamycin
US20080051381A1 (en) * 2006-08-22 2008-02-28 Burns Patrick J Suppression of estrus in mares by a single injection method
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
PL2421545T3 (pl) 2009-04-23 2018-05-30 Jbs United Animal Health Ii Llc Sposób i kompozycja do synchronizacji czasu inseminacji
CN101822636A (zh) * 2010-05-24 2010-09-08 中国人民解放军军事医学科学院放射与辐射医学研究所 可注射雌三醇缓控释给药系统
KR101256300B1 (ko) * 2011-01-25 2013-04-18 박영호 암퇘지에게 발정을 지속적으로 유도하여 인공수정하는 방법.
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2875791A1 (en) 2012-06-06 2013-12-12 Minitube Of America, Inc. Multi-compartment container for biological liquids
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104994865A (zh) 2012-11-28 2015-10-21 杰碧斯联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR101360830B1 (ko) * 2013-11-21 2014-02-11 (주)나비바이오텍 젖산을 함유한 동물의 난소 기능 불활 조성물
CN103918604B (zh) * 2014-04-25 2016-03-30 安顺德康农牧有限公司 一种种猪养殖繁育方法
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2963871A1 (en) * 2014-10-08 2016-04-14 Maamar ACHACHA Altrenogest formulation and uses thereof for estrus synchronisation in animals
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
JP6692037B2 (ja) * 2016-03-25 2020-05-13 学校法人麻布獣医学園 ブタの初乳作出法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN114145263A (zh) * 2021-11-26 2022-03-08 佳和农牧股份有限公司 一种新型丹系后备母猪诱情方式
CN117981715B (zh) * 2024-04-07 2024-07-09 中国农业大学 一种促进后备母猪初情期启动和改善发情障碍的后备母猪批次化养殖方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860701A (en) * 1968-04-22 1975-01-14 Searle & Co Method for use and compositions of 11-lower alkyl steroids and drug delivery system for the controlled elution of 11-lower alkyl steroids
SU549118A1 (ru) * 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
US3991750A (en) * 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4756907A (en) * 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
GB8428201D0 (en) * 1984-11-08 1984-12-19 Glaxo Group Ltd Biological preparations
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
KR960704578A (ko) * 1993-09-29 1996-10-09 에드워드 엘. 만델 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
FR2717688B1 (fr) * 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs

Also Published As

Publication number Publication date
CA2321102A1 (en) 1999-08-26
PL342402A1 (en) 2001-06-04
AU2685099A (en) 1999-09-06
EP1054675A1 (en) 2000-11-29
KR20010034494A (ko) 2001-04-25
JP2002503696A (ja) 2002-02-05
WO1999042110A1 (en) 1999-08-26
US6028057A (en) 2000-02-22
CN1291101A (zh) 2001-04-11

Similar Documents

Publication Publication Date Title
BR9908338A (pt) Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes
ATE309197T1 (de) Verfahren zur herstellung alkylierter salicylamide
DK0538443T3 (da) Fremgangsmåde og formuleringer til kontraception og til behandling af godartede gynækologiske forstyrrelser
ATE322892T1 (de) Stabilisierte tramadol formulierungen mit verzögerter freisetzung
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
ES2136624T3 (es) Implante biocompatible para regular la ovulacion en yeguas.
NZ315006A (en) Paroxetine controlled release compositions
FI905683A (fi) Menetelmä hidastetusti vapauttavan koostumuksen valmistamiseksi
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
DK0920309T3 (da) Konjugeret linolensyre til bevaring eller forøgelse af mineralindhold i knogler
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
ES2039226T3 (es) Procedimiento para preparar composiciones que contienen policarbofil.
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
MY126020A (en) Method of deterring birds from plant and structural surfaces
DE69942959D1 (de) Pferdesystem für die künstliche Befruchtung ohne chirurgischen Eingriff
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
AR240450A1 (es) Excluida su aplicacion en o sobre animales, derivados de acido oxamidico, procedimiento para su preparacion y composiciones parasiticidas que los contienen.
ES2149740T1 (es) Dispositivo de inseminacion artificial para animales de cria, particularmente, cerdas.
ES2155439T3 (es) Seleccion y aislamiento de microhongos utilizados para la lucha biologica contra los nematodos parasitarios en el animal.
BR0015060A (pt) Agentes para promover engorda de animais e método para promover engorda
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
NZ219300A (en) Veterinary composition for release of actives into the rumen
GT199800140A (es) Composicion farmaceutica antimastitica a base de extractos de origen natural y procedimientos para fabricarla.
ES2099226T3 (es) Composiciones farmaceuticas de liberacion programada.
MX9206516A (es) Parasiticidas de formazano, proceso para su preparacion y composicion parasiticida que los contiene.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.